Absorption

Global Thermally Conductive Plastics Market Trajectory & Analytics to 2026 - Miniaturization Trend Spurs Demand for Thermally Conductive Plastics - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 18, 2022 - 10:58am

The "Thermally Conductive Plastics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Thermally Conductive Plastics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Electrical & electronics, automotive, and lighting industry are the major end-use consumers for thermally conductive plastics.
  • LED lights are among the largest applications for thermally conductive plastics.
  • The rising demand for plastics is encouraging specialty chemicals players to offer thermally conductive polyamide compounds with high strain capability and superior impact resistance.

Needle-Free Platelet-Rich Plasma Grows Hair Through Thulium Laser Technology

Retrieved on: 
Wednesday, August 17, 2022 - 7:00pm

Beginning with a 60 cc blood draw, highly concentrated platelet-rich plasma isolate is obtained in the lab.

Key Points: 
  • Beginning with a 60 cc blood draw, highly concentrated platelet-rich plasma isolate is obtained in the lab.
  • However, many of these same growth factors have been shown in clinical studies to stimulate hair growth.
  • Getting the growth factors to the hair follicle has been the primary hurdle of platelet-rich plasma, which has typically been done by needle injection.Dr.
  • In 2005, Dr. Welter began a successful hair restoration practice and founded the New England Center for Hair Restoration.

Gelesis to Participate in Fireside Chat with IPO Edge Today at 2:00 PM ET

Retrieved on: 
Wednesday, August 17, 2022 - 1:00pm

Gelesis Holdings Inc. (NYSE: GLS) (Gelesis or the Company) the maker of Plenity for weight management, today announced that the Company is participating in a fireside chat with IPO Edge today at 2:00 PM ET.

Key Points: 
  • Gelesis Holdings Inc. (NYSE: GLS) (Gelesis or the Company) the maker of Plenity for weight management, today announced that the Company is participating in a fireside chat with IPO Edge today at 2:00 PM ET.
  • Gelesis Holdings Inc. (NYSE: GLS) (Gelesis) is a consumer-centered biotherapeutics company and the maker of Plenity, which is inspired by nature and FDA cleared to aid in weight management.
  • Our first-of-their-kind non-systemic superabsorbent hydrogels are made entirely from naturally derived building blocks.
  • Gelesis gives no assurance that any expectations set forth in this press release will be achieved.

Electrolit Welcomes Christian Patiño Webb as New Chief Executive Officer

Retrieved on: 
Wednesday, August 17, 2022 - 12:04pm

CERRITOS, Calif., Aug. 17, 2022 /PRNewswire/ -- Electrolit the preferred, premium hydration beverage made from pharmaceutical quality grade ingredients - is pleased to welcome Christian Patio Webbas the company's new Chief Executive Officer.

Key Points: 
  • CERRITOS, Calif., Aug. 17, 2022 /PRNewswire/ -- Electrolit the preferred, premium hydration beverage made from pharmaceutical quality grade ingredients - is pleased to welcome Christian Patio Webbas the company's new Chief Executive Officer.
  • "It is an exciting opportunity to lead a brand with the legacy and momentum that Electrolit has and even more with the potential moving forward," said Christian Patio Webb.
  • Earning his Bachelor of Science in Industrial Engineering from Universidad Anhuac and his MBA from Duke University, Patio Webb has the educational background for this role.
  • Working at Procter & Gamble for 7 years, Patio Webb gained experience with American multinational consumer goods.

Youtheory® Introduces New Line of Liquid and Capsule Supplements

Retrieved on: 
Tuesday, August 16, 2022 - 12:22pm

IRVINE, Calif., Aug. 16, 2022 /PRNewswire/ -- Southern California-based supplement company Youtheory® has launched a new line of Liquid Nutrient Packets and Capsules including B12B6, Ashwagandha, and K2D3. These ready-to-drink packets and easy-to-swallow capsules provide a daily serving that helps support overall mental and physical well-being.

Key Points: 
  • IRVINE, Calif., Aug. 16, 2022 /PRNewswire/ -- Southern California-based supplement company Youtheory has launched a new line of Liquid Nutrient Packets and Capsules including B12B6, Ashwagandha, and K2D3.
  • B12B6 liquid formula helps provide energy and brain health support in an easy-to-carry, convenient packet, perfect for your busy lifestyle with a delicious raspberry flavoring along with its capsule pairing.
  • Youtheory Ashwagandha liquid and capsule formula uses an organic full-spectrum extract, KSM-66 which is the most clinically supported Ashwagandha on the market.
  • Available in 12-packs, the liquid supplements are an easy, convenient and flavorful way to get in your daily nutrients.

INDIVA REPORTS SECOND QUARTER 2022 RESULTS

Retrieved on: 
Tuesday, August 16, 2022 - 12:00pm

LONDON, ON, Aug. 16, 2022 /PRNewswire/ - Indiva Limited (the "Company" or "Indiva") (TSXV: NDVA) (OTCQX: NDVAF), the leading Canadian producer of cannabis edibles and other cannabis products, is pleased to announce its financial and operating results for the second fiscal quarter ended June 30, 2022.

Key Points: 
  • LONDON, ON, Aug. 16, 2022 /PRNewswire/ - Indiva Limited (the "Company" or "Indiva") (TSXV: NDVA) (OTCQX: NDVAF), the leading Canadian producer of cannabis edibles and other cannabis products, is pleased to announce its financial and operating results for the second fiscal quarter ended June 30, 2022.
  • "The second quarter was extremely busy operationally, as we began manufacturing new products, including our first commercial batches of Pearls gummies, which were delivered to the OCS subsequent to quarter end.
  • Gross revenue in Q2 2022 was $8.9 million, representing an 8.3% sequential decrease from Q1 2022, and a 9.9% decrease year-over-year from Q2 2021.
  • Data from Hifyre Inc. for the second quarter of 2022 shows strong sell-through of Indiva edible products.

AUXLY REPORTS Q2 2022 FINANCIAL RESULTS

Retrieved on: 
Monday, August 15, 2022 - 12:25pm

FollowingtheacquisitionofAuxlyLeamingtoninNovember2021,theCompany recognizesgross profit or loss from Auxly Leamington as part of the costs of finished cannabis inventory sold only asproductissoldtotheCompany's customersafterbeingfurtherprocessed byAuxlyOttawaor Auxly Charlottetown.

Key Points: 
  • FollowingtheacquisitionofAuxlyLeamingtoninNovember2021,theCompany recognizesgross profit or loss from Auxly Leamington as part of the costs of finished cannabis inventory sold only asproductissoldtotheCompany's customersafterbeingfurtherprocessed byAuxlyOttawaor Auxly Charlottetown.
  • Prior to the acquisition of Auxly Leamington, the net operating results of Auxly Leamington were recorded in other income and expenses on an equity basis in proportion to the Company's ownership in the joint venture.
  • The net loss of $54.1 million through six months of 2022 includes the net impact of approximately $25.7 million related to the closure of the Auxly Annapolis and Auxly Annapolis OG facilities during the first quarter of 2022.
  • Please see the Company's MD&A dated June 30, 2022, under "Non-GAAP Measures" for a further description of the following financial and supplementary financial measures.

Plus Therapeutics Presents Positive Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases

Retrieved on: 
Saturday, August 13, 2022 - 6:06pm

The conference is co-sponsored by the Society for Neuro-Oncology (SNO) and the American Society of Clinical Oncology (ASCO) and is being held August 12-13, 2022 in Toronto, Canada.

Key Points: 
  • The conference is co-sponsored by the Society for Neuro-Oncology (SNO) and the American Society of Clinical Oncology (ASCO) and is being held August 12-13, 2022 in Toronto, Canada.
  • Importantly, all patients showed a decreased CSF cell count by microfluidic chamber assay after treatment, ranging from 65% to 92% which was also durable.
  • We look forward to continuing the clinical evaluation with additional dose escalations to further assess 186RNLs versatility and on behalf of patients in need.
  • Data show 186RNL treatment is safe and well-tolerated, with no adverse events (AEs) with outcome of death or discontinuations.

Beam Global Reports Fiscal Q2 2022 Financial Results

Retrieved on: 
Friday, August 12, 2022 - 9:10pm

SAN DIEGO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Beam Global , (Nasdaq: BEEM , BEEMW), (the Company), the leading provider of innovative sustainable products and technologies for electric vehicle (EV) charging, energy storage, energy security and outdoor media, today announced the financial results for the second fiscal quarter ended June 30, 2022.

Key Points: 
  • SAN DIEGO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Beam Global , (Nasdaq: BEEM , BEEMW), (the Company), the leading provider of innovative sustainable products and technologies for electric vehicle (EV) charging, energy storage, energy security and outdoor media, today announced the financial results for the second fiscal quarter ended June 30, 2022.
  • Beam Global reported record second quarter revenues of $3.7 million in the second fiscal quarter of 2022, compared to $2.1 million in the same period in the prior year, an increase of 75%.
  • Management will host a conference call on Friday August 12, 2022 at 4:30 PM ET to review financial results and provide an update on corporate developments.
  • Except to the extent required by law, Beam Global expressly disclaims any obligation to update any forward-looking statements.

Survey: Cardiovascular Patients on Aspirin Therapy Prefer VAZALORE® 81 mg

Retrieved on: 
Friday, August 12, 2022 - 12:00pm

SPARTA, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred together as “VAZALORE®”), today announced positive findings from its initial VAZALORE 81 mg Patient Experience Survey.

Key Points: 
  • The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred together as VAZALORE), today announced positive findings from its initial VAZALORE 81 mg Patient Experience Survey.
  • The kits included a VAZALORE 81 mg product sample, product literature and a high-value coupon.
  • Similar to the findings in the VAZALORE 81 mg Patient Experience Survey, my patients are highly satisfied with VAZALORE, and not experiencing any side effects, concluded Dr. Ali.
  • VAZALORE is an FDA-approved liquid-filled aspirin capsule, available in 81 mg and 325 mg doses.